Comment by Tommaso Costa

Using a log-normal model to allow for a fourfold uncertainty in early counts, the data are about 10 times more likely under the market-origin scenario than the lab-origin scenario. My calculation was a deliberately simple likelihood comparison: given some realistic-seeming starting assumptions and early case-count estimates, how well does each scenario generate the observed infections after the first month?